Type 2 Diabetes

More clinical data needed to green light new diabetes treatment for NHS use, NICE says

Inconsistent clinical trial data means more evidence is needed to recommend tirzepatide for NHS use, the National Institute for Health and Care Excellence (NICE) has announced.

Positioned by the manufacturer as an alternative to treatments like dulaglutide, liraglutide and semaglutide, tirzepatide is taken as a weekly injection to combat type 2 diabetes.

NICE’s independent committee saw that tirzepatide resulted in lower weight and better glucose control at any dose compared to semaglutide or insulin therapy.

                                                                            Video credit: Canva

The level of weight reduction scaled with the level of dose, however the effect on glucose control was not as consistent.

Despite the committee recognising the importance of new options given the difficulties with glucose control in the current crop of treatments, NICE has therefore asked the manufacturer to provide more data to address the uncertainties, as well as further analyses and clarifications on the submitted economic model.

“Type 2 diabetes is becoming more prevalent in society, so new treatment options are needed to help people with it to control their blood-glucose levels,” said NICE’s director of medicines evaluation, Helen Knight.

The accuracy of the forecasted long-term health benefits of tirzepatide compared to its alternatives remains a question, meaning NICE cannot establish whether the treatment is good value for money.

NICE has also requested the company provide more clarity around how its economic model compares to its peers’.

The committee’s decision is now subject to a consultation which can be contributed to until 18 July 2023 via NICE’s website.

The pricing around the pre-filled disposable injection pens will remain confidential until final guidance is published.

Image credit: iStock

NHE Nov/Dec 2023

NHE Nov/Dec 2023

AI is key in helping dementia patients live independently for longer.

The Nov/Dec 2023 edition of NHE brings you expert comment and analysis on a range of key health sector topics, from digital transformation to navigating post-pandemic challenges.


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Events

NHE has created a full calendar of events to address the most important issues that influence the delivery of healthcare services. Over 365 days you'll have the opportunity to hear from a range of highly motivating, informative and inspirational speakers. These speakers will equip you with the knowledge and unique insight to enable you to overcome the challenges that you face.

National Health Executive Podcast

Ep 39.
What makes a good NHS manager? with Anthony Painter, Director of Policy at Chartered Management Institute (CMI)

In episode 39 of the National Health Executive podcast, we were joined by Anthony Painter, who is the director of policy at the Chartered Management Institute (CMI), to discuss all things management within the UK health sector and NHS.

During the podcast, Anthony shared some of the recent research CMI conducted in partnership with the Social Market Foundation, which centred around the state of management and leadership within the NHS.

More articles...

View all